HCMP2MAG-19K

MILLIPLEX^® Human Complement Panel

Name: MILLIPLEX<SUP>®</SUP> Human Complement Panel
Brand: MM

Configurable Human Complement 6-Plex Panel 2

Synonym(s):

Human complement multiplex kit, Luminex^® human complement immunoassay, Millipore human complement panel

About This Item

UNSPSC Code:

12161503

NACRES:

NA.47

eCl@ss:

32161000

Key Documents

View All Documentation

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

MILLIPLEX^® Human Complement Panel, Configurable Human Complement 6-Plex Panel 2

species reactivity

human

manufacturer/tradename

Milliplex^®

Quality Level

200

packaging

1 ea of

assay range

accuracy: 95%
(Complement C3)
sensitivity: 0.024 ng/mL
(Complement Factor B)
sensitivity: 0.048 ng/mL
(Complement C1q)
sensitivity: 0.120 ng/mL
(Complement C3)
sensitivity: 0.135 ng/mL
(Complement Factor H)
sensitivity: 0.191 ng/mL
(Complement C4)
sensitivity: 3.639 ng/mL
(Complement C3b/iC3b)
standard curve range: 0.041-300 ng/mL
(Complement Factor H)
standard curve range: 0.08-60 ng/mL
(Complement C1q)
standard curve range: 0.08-60 ng/mL
(Complement Factor B)
standard curve range: 0.27-200 ng/mL
(Complement C3)
standard curve range: 0.55-400 pg/mL
(Complement C4)

technique(s)

multiplexing: suitable

input

serum plasma (Cell culture, cell culture supernatants)

detection method

fluorometric (Luminex^® xMAP^® technology)

shipped in

ambient
wet ice

storage temp.

2-8°C

Related Categories

Immunoassay Platform Solutions

MILLIPLEX^® Multiplex Assays for Luminex^® Instruments

Protein Biology

Biochem/physiol Actions

Cross Reactivty
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Preparation Note

Recommended storage for kit components is 2 - 8°C.

Legal Information

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Features and Benefits

Comprehensive 6-Plex Analyte Kit: This panel enables the simultaneous quantification of six essential complement proteins, including C1q, C3, C3b/iC3b, C4, Complement Factor B, and Complement Factor H, providing a holistic view of complement activation and regulation.
Advanced Luminex^® xMAP^® Technology: Utilizes a magnetic bead-based immunoassay format that ensures rapid, sensitive, and accurate detection of multiple analytes, enhancing the reliability of your research findings.
Insights into Complement Activation: By quantifying multiple complement proteins simultaneously, this panel helps researchers gain valuable insights into the complement system′s role in immune responses, inflammation, and disease mechanisms.
Enhanced Research Efficiency: The multiplex capability allows for significant increases in sample throughput, enabling researchers to analyze more samples in less time, which is crucial in high-demand research environments.
Critical for Disease Research: The complement system is implicated in various conditions, including autoimmune diseases, asthma, and neurological disorders. This kit enables researchers to explore the role of complement components in these diseases, potentially leading to new therapeutic targets.
Reliable Data for Publication: With built-in quality controls and high sensitivity, researchers can trust the results generated from this kit, ensuring that they meet the rigorous standards required for scientific publication.

General description

The complement system consists of a large number of plasma proteins that assist, or complement, the ability of phagocytic cells and antibodies to clear pathogens. Although it is part of the innate immune system, not adaptable and unchanging over the course of a lifetime, it can be recruited and activated by the adaptive immune system. The system proteins and glycoproteins that are synthesized primarily by hepatocytes normally circulate as inactive pro-proteins. Once stimulated the end result of the cascade is a massive amplification of response and activation of the membrane attack complex, which forms a transmembrane pore causing osmotic lysis of target cells. The complement system consists of three different simultaneous pathways. The classical pathway is stimulated by antigen-antibody complexes; the alternative pathway spontaneously activates on contact with pathogenic cell surfaces; the mannose-binding lectin pathway recognizes mannose sugars usually present only on pathogenic cell surfaces. The complement system is thought to play a key role in many diseases with an immune component, such as asthma or sepsis, and in many autoimmune diseases, including systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis. It is also becoming increasingly associated with neurological diseases, such as Alzheimer′s Disease, and conditions such as spinal cord injuries.

Application

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 6 analytes in human serum, plasma, and cell culture supernatants.

Analytes included: C1q, C3, C3b, C4, Factor B, Factor H

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

pictograms

GHS08,GHS05,GHS07,GHS09

signalword

Danger

hcodes

H302 + H312 + H332,H317,H318,H373,H411

pcodes

P273 - P280 - P302 + P352 + P312 - P304 + P340 + P312 - P305 + P351 + P338 - P314

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

Storage Class

10 - Combustible liquids

wgk

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Synaptic and complement markers in extracellular vesicles in multiple sclerosis.

Pavan Bhargava et al.

Multiple sclerosis (Houndmills, Basingstoke, England), 27(4), 509-518 (2020-07-17)

Synaptic loss is a feature of multiple sclerosis pathology that can be seen even in normal-appearing gray matter. Opsonization of synapses with complement components may underlie pathologic synapse loss. We sought to determine whether circulating neuronal-enriched and astrocytic-enriched extracellular vesicles

Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence.

Laura McCulloch et al.

F1000Research, 8, 1039-1039 (2019-11-12)

Background: Blockade of the cytokine interleukin-1 (IL-1) with IL-1 receptor antagonist (IL-1Ra) is a candidate treatment for stroke entering phase II/III trials, which acts by inhibiting harmful inflammatory responses. Infection is a common complication after stroke that significantly worsens outcome

Elevated Adipsin and Reduced C5a Levels in the Maternal Serum and Follicular Fluid During Implantation Are Associated With Successful Pregnancy in Obese Women.

Manjunath Ramanjaneya et al.

Frontiers in endocrinology, 13, 918320-918320 (2022-08-02)

Complement factors mediate the recruitment and activation of immune cells and are associated with metabolic changes during pregnancy. The aim of this study was to determine whether complement factors in the maternal serum and follicular fluid (FF) are associated with

Serological and cellular inflammatory signatures in end-stage kidney disease and latent tuberculosis.

Milla R McLean et al.

Clinical & translational immunology, 10(11), e1355-e1355 (2021-11-13)

Tuberculosis comorbidity with chronic diseases including diabetes, HIV and chronic kidney disease is of rising concern. In particular, latent tuberculosis infection (LTBI) comorbidity with end-stage kidney disease (ESKD) is associated with up to 52.5-fold increased risk of TB reactivation to

High Endurance Elite Athletes Show Age-dependent Lower Levels of Circulating Complements Compared to Low/Moderate Endurance Elite Athletes.

Shamma Al-Muraikhy et al.

Frontiers in molecular biosciences, 8, 715035-715035 (2021-10-12)

Introduction: Aerobic exercise activates the complement system in the peripheral blood. However, the effect of age and high intensity endurance training on the levels of circulating complements and sassociated inflammatory cytokines, oxidative stress markers and cellular aging remains unknown. Methods:

View All Related Papers

MILLIPLEX® Human Complement Panel